Core Viewpoint - The Oncology Institute, Inc. (TOI) has announced a private placement expected to generate approximately $16.5 million in gross proceeds, aimed at supporting organic growth and working capital needs [1][5]. Group 1: Private Placement Details - The private placement involves accredited investors and includes participation from existing investors and members of the management team and Board of Directors [1]. - Each unit in the private placement consists of two shares of common stock (or pre-funded warrants) and common warrants to purchase one share of common stock at a price of $2.2084 per unit [2]. - The pre-funded warrants will have an exercise price of $0.0001 per share, while the common warrants will have an exercise price of $1.1980 per share [2]. Group 2: Exchange Agreement - Deerfield Management Company has agreed to exchange approximately $4.1 million of the Company's senior secured convertible notes for 37,232.83 shares of common-equivalent preferred stock and warrants to purchase 1,861,642 shares of common stock at the same prices as the private placement [4]. Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to support organic growth and working capital needs [5]. Group 4: Company Overview - Founded in 2007, TOI is one of the largest value-based community oncology groups in the U.S., providing specialized cancer care to over 1.8 million patients [8]. - The organization employs over 120 clinicians and has more than 700 team members across over 70 clinic locations [8].

Core Viewpoint - The Oncology Institute, Inc. (TOI) will announce its fourth quarter and full year 2024 financial results on March 25, 2025, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - TOI will release its financial results after market close on March 25, 2025 [1]. - A conference call will take place on the same day at 5:00 p.m. Eastern Time [1]. Group 2: Conference Call Access - The conference call can be accessed by phone at 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2]. - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13750791 [2]. - The replay will be available until April 1, 2025 [2]. Group 3: Company Overview - Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients [4]. - The company employs over 120 clinicians and has more than 700 teammates across over 70 clinic locations [4]. - TOI provides advanced cancer care services, including clinical trials and transfusions, aiming to improve oncology care delivery [4].

Core Insights - Topicus.com Inc. reported strong financial results for Q4 and the full year 2024, with total revenue reaching €364.9 million for the quarter and €1,294.9 million for the year, marking increases of 18% and 15% respectively compared to 2023 [5][8] - The company's net income for Q4 2024 was €56.2 million, a 32% increase from €42.5 million in Q4 2023, while the annual net income rose to €149.5 million, up 30% from €115.4 million in 2023 [6][8] - Cash flows from operations (CFO) also saw significant growth, increasing by 28% to €79.6 million in Q4 and by 41% to €347.6 million for the full year [7][8] Financial Performance - Total revenue for Q4 2024 was €364.9 million, up from €309.7 million in Q4 2023, driven by acquisitions and organic growth of 5% [5][8] - For the full year 2024, total revenues were €1,294.9 million, compared to €1,125.0 million in 2023, with organic growth also at 5% [5][8] - Net income for Q4 2024 was €56.2 million, translating to €0.40 per share, compared to €42.5 million (€0.31 per share) in Q4 2023 [6][8] - Annual net income increased to €149.5 million (€1.11 per share) from €115.4 million (€0.88 per share) in 2023 [6][8] Cash Flow and Acquisitions - CFO for Q4 2024 increased to €79.6 million from €62.4 million in Q4 2023, representing a 28% growth [7][8] - For the full year, CFO rose to €347.6 million from €246.6 million, a 41% increase [7][8] - Free cash flow available to shareholders (FCFA2S) for Q4 2024 was €36.6 million, up 27% from €28.9 million in Q4 2023, and for the full year, it increased to €177.4 million from €123.4 million, a 44% rise [9][8] - The company completed acquisitions for a total cash consideration of €153.4 million in 2024, including holdbacks and contingent considerations [8] Balance Sheet Highlights - As of December 31, 2024, total assets were €1,535.9 million, up from €1,432.8 million in 2023 [15][16] - Current assets included cash of €206.2 million and accounts receivable of €142.8 million [15] - Total liabilities increased to €1,004.5 million from €840.3 million in 2023, with current liabilities including a revolving credit facility of €225.7 million [16] Shareholder Returns - The company paid dividends totaling €127.6 million to shareholders in 2024 [26] - Retained earnings as of December 31, 2024, were €266.3 million, down from €297.4 million in 2023 [21][23]

Core Viewpoint - The Oncology Institute, Inc. (TOI) has amended its facility agreement with Deerfield Management Company, allowing for greater financial flexibility and a partial paydown of senior secured convertible notes [1][2][3]. Financial Agreement - Deerfield has waived certain restrictions on TOI's ability to offer and sell equity and removed the minimum cash covenant of $40 million [2]. - TOI has paid down approximately $20 million of the senior secured convertible notes along with accrued and unpaid interest [2]. Growth Initiatives - TOI has signed three new capitation agreements year to date, adding approximately 80,000 lives across California, Nevada, and Florida [3]. - The total lives under value-based agreements in Florida now exceed 200,000, with over 50,000 under Medicare Advantage [3]. Company Overview - Founded in 2007, TOI is a leading provider of value-based cancer care in the community setting, serving over 1.8 million patients [4]. - The company employs over 120 clinicians and has more than 700 teammates across over 70 clinic locations [4].

Group 1 - Topicus.com Inc. plans to release its fourth quarter results on February 26, 2025 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on the release date [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus specializes in acquiring, managing, and building vertical market software businesses [2]

Group 1 - Topicus.com Inc. has announced the acquisition of 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share from Cyfrowy Polsat S.A. [1] - Topicus.com Inc.'s subsidiaries Yukon Niebieski Kapital B.V. and TSS Europe B.V. have signed a shareholders' agreement with the Adam Góral Family Foundation to govern their cooperation regarding their shareholdings in Asseco Poland S.A. [1] - The shareholders' agreement will take effect upon the completion of Yukon's acquisition of 12,318,863 treasury shares from Asseco Poland S.A., representing 14.84% of the company's share capital, also at a price of 85 PLN per share [1] Group 2 - Asseco Group operates in the information technology sector and has a presence in 62 countries, offering proprietary IT solutions across various economic sectors [3] - The Adam Góral Family Foundation, established by the CEO of Asseco Poland, operates under the Polish Family Foundation Act and is registered in Rzeszów, Poland [4] - Topicus.com Inc. is a leading provider of vertical market software in Europe, focusing on acquiring and managing software companies that provide specialized solutions for public and private sector clients [5]

Group 1 - Topicus.com Inc. announced the acquisition of 8,300,029 shares in Asseco Poland S.A. from Cyfrowy Polsat S.A., representing approximately 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share [1] - Asseco Group operates in 62 countries and is engaged in information technology, offering comprehensive IT solutions for all sectors of the economy [2] - Topicus.com Inc. is a pan-European provider of vertical market software and platforms, focusing on long-term growth potential in various European markets [3] Group 2 - Cyfrowy Polsat S.A. is a leading media and telecom group in Poland, providing digital pay-TV, telephony, broadband internet, and operating in renewable energy [4]

Core Insights - Florida Blue has launched a new oncology care model aimed at improving access to high-quality cancer care for its myBlue members, developed in collaboration with Sanitas Medical Centers and The Oncology Institute [1][4] - The program focuses on personalized, evidence-based treatment plans and emphasizes collaboration between oncologists and primary care providers to enhance patient outcomes and overall health [3][4] Company Overview - Florida Blue is the leading health insurer in Florida, serving over six million members across all 67 counties and has been in operation for more than 80 years [6] - The Oncology Institute is a prominent value-based oncology group in the U.S., providing high-quality cancer care at 14 locations in Central and South Florida [2][12] - Sanitas Medical Centers offers comprehensive primary care to nearly half a million Florida Blue members through 60 locations [2] Program Details - The new oncology care model connects myBlue members diagnosed with cancer to their own TOI oncology team, ensuring personalized treatment plans and support from primary care providers [3] - The program aims to facilitate seamless communication and coordination among healthcare providers, patients, and their families, enhancing the overall care experience [3][4] Enrollment Information - Individuals not currently enrolled in myBlue can sign up during the Marketplace open enrollment period, which ends on January 15, or at any time if they qualify for special enrollment [5]

Core Insights - Grapevine's digital supply chain solutions have enabled The Oncology Institute (TOI) to achieve over $1.7 million in medical supply savings year to date, with monthly savings reaching 61% in July 2024, highlighting the effectiveness of these innovations in healthcare [2][6]. Group 1: Cost Savings and Efficiency - The Oncology Institute's significant savings demonstrate the potential of Grapevine's digital procurement platform to eliminate inefficiencies in healthcare supply chains, ultimately reducing costs for patients [3][4]. - Grapevine's platform enhances the reliability and efficiency of healthcare supply chains by providing visibility into inventory levels, recommending alternative suppliers, and enabling seamless order tracking, which allows medical facilities to maintain high-quality care [5][6]. Group 2: Strategic Partnerships and Supplier Diversification - The partnership between Grapevine and TOI has allowed for a diversified supplier network, reducing reliance on single-source distributors and mitigating risks associated with supply shortages and inflated prices [4][7]. - By leveraging AI-driven procurement solutions, TOI has increased competition among suppliers, leading to lower costs and a more resilient supply chain [4][5]. Group 3: Industry Transformation - The success of Grapevine's platform underscores the importance of modernizing healthcare supply chains through digital transformation, promoting a future of cost-effective, resilient, and patient-centered care [6][7].

The Oncology Institute, Inc. (NASDAQ:TOI) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology Institute's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the conference over to Mark Hueppelsheuser, General Counsel at TOI. Thank you ...